Cargando…
Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer
SIMPLE SUMMARY: The development of drug resistance in HER2 targeted therapies poses a major challenge in breast cancer treatment. To address this challenge, researchers have adopted two main strategies: repurposing existing drugs to enhance their effectiveness and identifying new targets to broaden...
Autores principales: | Cao, Yi, Li, Yunjin, Liu, Ruijie, Zhou, Jianhua, Wang, Kuansong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177527/ https://www.ncbi.nlm.nih.gov/pubmed/37174034 http://dx.doi.org/10.3390/cancers15092568 |
Ejemplares similares
-
HER-2-positive primary neuroendocrine neoplasms of the breast with signet ring feature: A case report and review of literature
por: Li, Yunjin, et al.
Publicado: (2022) -
Corrigendum: HER-2 positive primary neuroendocrine neoplasms of the breast with signet ring feature: A case report and review of literature
por: Li, Yunjin, et al.
Publicado: (2023) -
Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
por: Wu, Xiaofan, et al.
Publicado: (2022) -
Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019) -
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)